Insulin degludec + liraglutide

Insulin degludec + liraglutide has been studied in 11 papers since 2021: 2 trials and 3 observational studies in people, 1 in cells, 4 reviews; 5 in the past year. It is an approved medicine.

InterventionApproved 2014

11 papers study it1 more mentions it18 findingsUpdated

PubChemPubChemChEBI

See all 11 papers on insulin degludec + liraglutide

At a glance

Independent labs found the same change in people. 4 independent labs in 2 countries; 25 trials, 2 about aging, 6 with no results posted.

“fat-free mass (+ 3.17 kg/m), body cell mass (+ 7.82 kg/m), phase angle (+ 1.75°), and basal metabolic rate (+ 217.6 kcal) all increased (p < 0.001)”
Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodellingEuropean geriatric medicine2025doi:10.1007/s41999-025-01271-3

2 of its findings point the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 4 independent labs in 2 countries
  • 2 findings against
  • 25 trials, 2 about aging, 6 with no results posted
  • Funders: Novo Nordisk and 1 more
  • 5 of 16 findings with company ties
  • Human trial2
  • Humans3
  • In silico1

Studies in people

2 studies gave insulin degludec + liraglutide to people and measured what changed.

What changedDesignPeopleSource

up: Increases Alistipes

Trialsix months24 people12 women, 23 menmean age, 81.4 yearsPatients who replaced their pre-existing hypoglycemic therapeutic regimen with a flexibly-timed single daily dose of degludeg and liraglutide fixed combinationAging and disease, Apr 1, 2023

up: Improves DTSQ11.08 (95% CI 7.13–15.02)

down: Decreases HbA1c-0.58 (95% CI -1.08 to -0.08)

down: Decreases TNF-alpha-1.83 (95% CI -3.12 to -0.54)

Trial6 months35 peopleBoth≥ 75 yearsOlder adults; type 2 diabetesBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Oct 19, 2021

What did studies of insulin degludec + liraglutide find?

12

Studies of insulin degludec + liraglutide measured 12 outcomes; the most studied are HbA1c (5 studies) and body weight (2).

HbA1c

downin humans5

5 studies
  1. Insulin degludec + liraglutide decreases HbA1c in humans (frail older adults with T2DM) (7.29% to 7.05%).

    Human trialfrail older adults with T2DM6 monthsn = 36

  2. Insulin degludec + liraglutide decreases HbA1c in humans (type 2 diabetes) (-0.58 (95% CI -1.08 to -0.08)).

    Human trialtype 2 diabetes6 monthsn = 35

  3. Insulin degludec + liraglutide is linked with lower HbA1c in humans (type 2 diabetes) (-1.08% (SD 1.87, p < 0.001)).

    Humanstype 2 diabetes180 daysn = 3,062

  4. Insulin degludec + liraglutide is linked with lower HbA1c in humans (older adults with T2DM on insulin therapy).

    Humansolder adults with T2DM on insulin therapy6 monthsn = 96

  5. Insulin degludec + liraglutide decreases HbA1c in humans (real-world head-to-head studies in adults with type 2 diabetes).

    Reviewreal-world head-to-head studies in adults with type 2 diabetes

More on HbA1c

Body weight

downin humans2

2 studies
  1. Insulin degludec + liraglutide decreases body weight in humans (frail older adults with T2DM) (-2.6 kg).

    Human trialfrail older adults with T2DM6 monthsn = 36

  2. Insulin degludec + liraglutide decreases body weight in humans (real-world head-to-head studies in adults with type 2 diabetes).

    Reviewreal-world head-to-head studies in adults with type 2 diabetes

Alistipes

upin humans1

1 study
  1. Insulin degludec + liraglutide increases Alistipes in responders.

    Human trialin responderssix monthsn = 13

  2. Insulin degludec + liraglutide increases Alistipes in humans (responders with decreased HbA1c) (p=0.013).

    Human trialresponders with decreased HbA1cgut6 monthsn = 13

More on Alistipes

Treatment-emergent adverse events

upin humans1OR 1.69

1 study
  1. Insulin degludec + liraglutide increases treatment-emergent adverse events in humans (compared to IDegAsp in type 2 diabetes) (OR 1.69, 95% CI 1.08-2.65).

    Reviewcompared to IDegAsp in type 2 diabetes

Daily insulin dose

downin humans1

1 study
  1. Insulin degludec + liraglutide is linked with lower daily insulin dose in humans (type 2 diabetes) (-4.95 U/day (SD 21.93, p < 0.001)).

    Humanstype 2 diabetes180 daysn = 3,062

insulin resistance

downin humans1

1 study
  1. Insulin degludec + liraglutide decreases insulin resistance in humans (frail older adults with T2DM) (42.39 to 32.84).

    Human trialfrail older adults with T2DM6 monthsn = 36

Fat-free mass

upin humans1

1 study
  1. Insulin degludec + liraglutide increases fat-free mass in humans (frail older adults with T2DM) (+3.17 kg/m).

    Human trialfrail older adults with T2DM6 monthsn = 36

Level 2 hypoglycemia

downin humans1

1 study
  1. Insulin degludec + liraglutide is linked with lower level 2 hypoglycemia in humans (older adults with T2DM on insulin therapy) (IR 0.04, 95 % CI 0.01-0.32, p < 0.001).

    Humansolder adults with T2DM on insulin therapy3 monthsn = 96

More on Level 2 hypoglycemia

Level 1 hypoglycemia

downin humans1

1 study
  1. Insulin degludec + liraglutide is linked with lower level 1 hypoglycemia in humans (older adults with T2DM on insulin therapy) (IR 0.08, 95 % CI 0.02-0.34, p < 0.001).

    Humansolder adults with T2DM on insulin therapy6 monthsn = 96

More on Level 1 hypoglycemia

Cognitive function

upin humans1

1 study
  1. Insulin degludec + liraglutide improves cognitive function in humans (type 2 diabetes) (p = 0.02).

    Human trialtype 2 diabetes6 monthsn = 35

TNF-alpha

downin humans1

1 study
  1. Insulin degludec + liraglutide decreases TNF-alpha in humans (type 2 diabetes) (-1.83 (95% CI -3.12 to -0.54)).

    Human trialtype 2 diabetes6 monthsn = 35

More on TNF-alpha

DTSQ

upin humans1

1 study
  1. Insulin degludec + liraglutide improves DTSQ in humans (type 2 diabetes) (11.08 (95% CI 7.13–15.02)).

    Human trialtype 2 diabetes6 monthsn = 35

More on DTSQ

Has insulin degludec + liraglutide been tested in people?

2 of 25 about aging

Yes: 2 trials and 3 observational studies in people have been published, and 25 trials are registered.

Approved

Repurposing

Who is developing insulin degludec + liraglutide?

1 company: Tonghua Dongbao Pharmaceutical.

Companies
  • Tonghua Dongbao PharmaceuticalPhase 3type 2 diabetes

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 2Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 04 papers in 12 months

See all 11 papers on insulin degludec + liraglutide